SequelSEC

BRAINSTORM CELL THERAPEUTICS INC. BCLI

Biological Products, (No Diagnostic Substances) · CIK 0001137883 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$3.61M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported net income of -$3.86M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BRAINSTORM CELL THERAPEUTICS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

BRAINSTORM CELL THERAPEUTICS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$3.61MUnavailable-$2.24M-$2.05MUnavailableUnavailable-$3.19M-$3.05MUnavailableUnavailable
Net income-$3.86MUnavailable-$2.43M-$2.11MUnavailableUnavailable-$2.97M-$2.71MUnavailableUnavailable
Research & development$963.00KUnavailable$852.00K$899.00KUnavailableUnavailable$1.72M$1.04MUnavailableUnavailable
Weighted-average diluted sharesshares 11.03MUnavailableUnavailableshares 11.01MUnavailableUnavailableUnavailableshares 5.31MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.35UnavailableUnavailable$-0.19UnavailableUnavailableUnavailable$-0.51UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.65MUnavailable$1.39M$1.15MUnavailableUnavailable$1.47M$2.00MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BRAINSTORM CELL THERAPEUTICS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$22.00KUnavailable$29.00K$5.00KUnavailableUnavailable$187.00K$168.00KUnavailableUnavailable
Total assets$788.00KUnavailable$1.02M$1.38MUnavailableUnavailable$1.83M$2.02MUnavailableUnavailable
Current assets$316.00KUnavailable$307.00K$508.00KUnavailableUnavailable$385.00K$364.00KUnavailableUnavailable
Total liabilities$12.38MUnavailable$11.01M$9.07MUnavailableUnavailable$9.60M$8.08MUnavailableUnavailable
Current liabilities$12.38MUnavailable$11.01M$9.02MUnavailableUnavailable$8.98M$7.08MUnavailableUnavailable
Total equity incl. NCI-$11.60MUnavailable-$9.98M-$7.69MUnavailableUnavailable-$7.76M-$6.06MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$7.49MUnavailable$7.07M$6.42MUnavailableUnavailable$6.08M$4.60MUnavailableUnavailable

Cash flow

BRAINSTORM CELL THERAPEUTICS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$895.00KUnavailable-$740.00K-$1.10MUnavailableUnavailable-$1.05M-$3.30MUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$898.00KUnavailable$780.00K$313.00KUnavailableUnavailable$1.06M$0UnavailableUnavailable
Net change in cash$3.00KUnavailable$40.00K-$789.00KUnavailableUnavailable$22.00K-$3.30MUnavailableUnavailable
Stock-based compensationUnavailableUnavailable$143.00K$660.00KUnavailableUnavailable$156.00K$178.00KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BRAINSTORM CELL THERAPEUTICS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.03xUnavailable0.03x0.06xUnavailableUnavailable0.04x0.05xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCLI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.